A Phase 1 interventional study of LY3537031 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Active, not recruiting at 5 sites in United States. Open to participants aged 22 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 52nd largest by planned enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 40 in phase 1, reaches primary completion later than 4 of the 54 other live ones, and was the 54th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 302 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 267 across the 117 interventional studies. Of the 61 that completed or were terminated, 29 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
29 of the studies in Obesity by Eli Lilly and Company that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
Add all 29 to your calendar (.ics) → With an account.
Among the 118 studies in Obesity by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.
Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 302 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a within the range of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple-ascending doses of LY3537031 administered subcutaneously (SC)
Drug: LY3537031
Placebo administered SC
Drug: Placebo
Multiple-ascending doses of LY3537031 administered SC
Drug: LY3537031
Placebo administered SC
Drug: Placebo
Multiple-ascending doses of LY3537031 administered SC
Drug: LY3537031
Placebo administered SC
Drug: Placebo
Multiple-ascending doses of LY3537031 administered SC
Drug: LY3537031
Placebo administered SC
Drug: Placebo
Administered SC
Administered SC
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline to Study Completion (Up to 56 Weeks)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3537031
Time frame: Predose on Day 1 through Week 56
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3537031
Time frame: Predose on Day 1 through Week 56
Pharmacodynamic (PD): Change from Baseline in Body Weight
Time frame: Baseline up to Week 56
PD: Change from Baseline in Fasting Glucose
Time frame: Baseline up to Week 56
PD: Change from Baseline in Oral Glucose Tolerance Test (OGTT) Results
Time frame: Baseline up to Week 56
PD: Change from Baseline in AUC of Glucose
Time frame: Baseline Up to Week 56
PD: Change from Baseline in Insulin Levels
Time frame: Baseline Up to Week 56
PD: Change from Baseline in Connecting Peptide (C-peptide) Levels
Time frame: Baseline Up to Week 56
PD: Change from Baseline in Cmax of Acetaminophen to Assess the Delay in Gastric Emptying
Time frame: Baseline up to Week 56
PD: Change from Baseline in AUC of Acetaminophen to Assess the Delay in Gastric Emptying
Time frame: Baseline Up to Week 56
PD: Change from Baseline in Time to Peak Drug Concentration (Tmax) of Acetaminophen to Assess the Delay in Gastric Emptying
Time frame: Baseline Up to Week 56
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 26 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jul 2026 → Nov 2026 and completion Jul 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brenipatide